INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average Price Target from Brokerages
INmune Bio, Inc. (NASDAQ:INMB – Get Free Report) has received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price […]
INmune Bio, Inc. (NASDAQ:INMB – Get Free Report) has received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price […]
